Neuropathic Ocular Pain Nop Market Insight

DelveInsight’s ‘Neuropathic Ocular Pain (NOP)—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the NOP, historical and forecasted epidemiology as well as the NOP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.

 

The NOP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM, NOP market size from 2018 to 2030. The Report also covers current NOP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Neuropathic Ocular Pain (NOP) Disease Understanding and Treatment Algorithm

Neuropathic Ocular Pain (NOP) Overview

Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves. Aberrant regeneration with upregulation of nociceptors responsible for the processing of painful stimuli leads to hyper-responsivity and increased perception of pain in response to even normally unpainful stimuli. The distorted neuronal excitability which persists even after the tissue has healed is the basis of symptoms of self-sustained chronic corneal pain persisting even in the absence of stimuli and clinical signs – the so-called corneal “pain without stain” or “phantom cornea.” This condition is the ocular analog of systemic neuropathic pain, complex regional pain syndrome, or reflex sympathetic dystrophy (RSD).

 

Symptoms of NOP include a host of ocular pain symptoms that have been described as dryness (with minimal or no relief with over-the-counter lubricating drops), burning, shooting, pressure-like pain, foreign body sensation, grittiness, aching, stabbing or cutting sensation and/or throbbing. Pain may occur spontaneously or be evoked by light (e.g., fluorescent room lights, sunlight), wind (e.g., indoor fans, in-clinic “air puff test” for eye pressure), and/or temperature changes (e.g., air conditioning, hairdryers, seasonal variation). One or both eyes may be involved. The onset may be sudden, as is usually when there is an identifiable trigger (such as trauma or surgery to the eye) or insidious. While the pain is typically chronic, its severity can range from mild to excruciating.

Continued in the report…..

 

Neuropathic Ocular Pain (NOP) Diagnosis

Diagnosing NCP has been challenging for vision care providers, partly due to the lack of understanding of this disease, as well as due to minimal or absent clinical signs, thus masking the underlying condition. NCP is typically diagnosed based on clinical history, symptoms, ophthalmological examination, and evidence of nerve injury (by in vivo confocal microscopy [IVCM]) and/or nerve dysfunction (nerve function tests). Patients typically complain of prolonged dry eye treatment, multiple treatment failures, note an inciting event (e.g., infection or surgery), and may complain about non-ocular pain, neurological, or psychiatric conditions upon questioning.

Continued in the report…..

 

Neuropathic Ocular Pain (NOP) Treatment

Devising management strategies for Neuropathic Corneal Pain (NCP) patients requires differentiation of peripheral, mixed, and centralized sources of pain. Therapies for NCP can be derived from therapeutic approaches for systemic neuropathic pain and ocular post-herpetic neuralgia. Medical records reviews by experts suggest that there are nearly 100 new NCP patients treated every year.

 

Peripheral sensitization in NCP is initiated by corneal nerve injury and subsequent inflammation. Recently, therapeutic strategies targeting neuronal regeneration have been shown to alleviate patient symptoms with autologous serum tears (AST). The rationale for this approach was based on previous reports from preclinical non-ocular neuropathic pain models on the use of neurotrophic factors, in particular, nerve growth factor (NGF). NGF reduced allodynia and hyperalgesia through reduction of reactive astrocytosis and glial modulation.

Continued in the report…..

Neuropathic Ocular Pain (NOP) Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Several Eye Disorders and Surgeries, and Total Cases of Neuropathic Ocular Pain (NOP) scenario in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan from 2018 to 2030.

 

Key Findings

  • In 2020, the total cases of Neuropathic Ocular Pain (NOP) were 2,904,412 cases in the 7MM, which might increase by 2030.
  • In 2020 the US accounted for 664,826 NOP cases, which is anticipated to increase by 2030.
  • In 2020, the EU5 countries accounted for 1,549,516 cases, which is seen to increase by 2030.
  • Among EU5 countries, Italy had the highest number of cases of Neuropathic Ocular Pain (NOP), which were 522,268 cases in 2020. As per DelveInsight’s estimates, this count will increase through the study period.
  • Japan, in 2020, accounted for 690,070 cases of NOP, which will decrease by the year 2030.

Country-Wise Neuropathic Ocular Pain (NOP) Epidemiology

The epidemiology segment also provides the NOP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.

Neuropathic Ocular Pain (NOP) Drug Chapters

NOP Emerging Drugs

 

SAF312: Novartis

SAF312 is a non-narcotic analgesic and TRPV cation channel antagonist designed to treat postoperative ocular pain.  The transient receptor potential vanilloid (TRPV) subfamily consists of six members and is divided into four groups based on homology: TRPV1/TRPV2, TRPV3, TRPV4, and TRPV5/TRPV6. Compared to other TRPV channels, TRPV1 is the major channel for detecting and integrating nociceptive chemical and thermal stimuli in sensory nerve fibers (thin myelinated Ad-fibers and unmyelinated C fibers), innervating most organs. TRPV1 activation initiates inflammation and the transmission of pain signals. The noxious signal generated by the activated TRPV1 can be blocked by a TRPV1 antagonist, and multiple molecules have been developed as TRPV1 antagonists, such as SAF312 by Novartis.

Products detail in the report…

List to be continued in the report…

Neuropathic Ocular Pain (NOP) Market Outlook

Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. Aberrant regeneration with upregulation of nociceptors responsible for the processing of painful stimuli leads to hyper-responsivity and increased perception of pain in response to even normally unpainful stimuli.

 

Severe pain sensation and light sensitivity prevent those afflicted with ocular neuropathic pain from performing daily living activities and are associated with symptoms of anxiety and depression. Treatment strategies encompass several approaches.

 

Recommended first-line topical treatments include neuro-regenerative and anti-inflammatory agents, whilst first-line systemic pharmacotherapy includes tricyclic antidepressants and anticonvulsant. Second-line oral treatments recommended include the opioid-antagonist and opiate analgesics. Complementary and alternative treatments, such as cardio exercise, acupuncture, omega-3 fatty acid, and gluten-free diet, may have additional benefits, as do potential non-invasive and invasive procedures in recalcitrant cases.

 

Devising management strategies for NCP patients requires differentiation of peripheral, mixed, and centralized sources of pain. Treatment in these cases will aim to decrease corneal nerves' sensitivity or shield them from the environment. One option is soft or scleral contact lenses, which protect the cornea from air drafts and temperature changes. Alternatively, autologous serum or plasma drops might help repair the nerves and make them respond more normally. These treatments are often used as first-line therapy. A dry eye should also be treated if there is evidence of it as a trigger.

Continued in the report…..

 

Key Findings

  • Overall Neuropathic Ocular Pain (NOP) market in the 7MM, is expected to reach USD 172 million by 2030.
  • The market size in the EU5 is expected to increase to USD 30.5 million by 2030 due to the rising awareness of the disease and launch of the emerging therapies.
  • The United States is expected to capture the largest market share of NOP by 2030 with USD 58.6 million market in 2020.
  • The expected launch of potential therapy shall increase the market size in the coming years, assisted by an increase in the population of NOP during the forecast period (2021–2030).

 

The United States Market Outlook

This section provides the total NOP market size and; market size by therapies in the United States.

 

EU-5 Market Outlook

The total NOP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total NOP market size and market size by therapies in Japan are provided.

Neuropathic Ocular Pain (NOP) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the NOP market or expected to get launched in the market during the study period 2018–2030. The analysis covers the NOP market uptake by drugs; patient uptake by therapies; and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuropathic Ocular Pain (NOP) Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for NOP emerging therapies.

Reimbursement Scenario in Neuropathic Ocular Pain (NOP)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the NOP market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of NOP, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the NOP epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for NOP is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the NOP market; historical and forecasted is included in the report, covering the 7MM, drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM. NOP market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the NOP market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence NOP R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for NOP. The launch of emerging therapies will significantly impact the NOP market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

NOP Report Insights

  • Patient Population
  • Therapeutic Approaches
  • NOP Pipeline Analysis
  • NOP Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

NOP Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • NOP Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

NOP Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the NOP market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the NOP total market size as well as market size by therapies across the 7MM, during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest NOP market size during the forecast period (2021–2030)?
  • At what CAGR, the NOP market is expected to grow at the 7MM, level during the forecast period (2021–2030)?
  • What would be the NOP market outlook across the 7MM, during the forecast period (2021–2030)?
  • What would be the NOP market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of NOP?
  • What is the historical NOP patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan?
  • What would be the forecasted patient pool of NOP at the 7MM, level?
  • What will be the growth opportunities across the 7MM, with respect to the patient population pertaining to NOP?
  • Out of the above-mentioned countries, which country would have the highest incident population of NOP during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM, during the forecast period (2021–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of NOP along with the approved therapy?
  • What are the current treatment guidelines for the treatment of NOP in the US and Europe?
  • What are the NOP marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of NOP?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of NOP?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NOP therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for NOP and their status?
  • What are the key designations that have been granted for the emerging therapies for NOP?
  • What are the 7MM, historical and forecasted market of NOP?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving NOP.
  • To understand the future market competition in the NOP market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for NOP in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the NOP market.
  • To understand the future market competition in the NOP market.

1. Key Insights

2. Report Introduction

3. Neuropathic Ocular Pain (NOP) Market Overview at a Glance

3.1. Market Share (%) of Neuropathic Ocular Pain (NOP) by Therapies in 2018

3.2. Market Share (%) of Neuropathic Ocular Pain (NOP) by Therapies in 2030

4. Future Prospects

5. Executive Summary of Neuropathic Ocular Pain (NOP)

6. Key Events

7. Neuropathic ocular pain (NOP): Disease Background and Overview

7.1. Introduction

7.2. Symptoms

7.3. Types

7.4. Causes

7.5. Pathophysiology of Neuropathic Corneal Pain

7.6. Diagnosis and Differential Diagnosis

7.6.1. Ocular Pain Questionnaires to Assess Symptoms

7.6.2. Functional Somatosensory Testing

7.6.3. Clinical Examination

7.6.4. In Vivo Confocal Microscopy (IVCM) to Confirm Corneal Nerve Damage

7.7. Treatment and Management

7.7.1. Neuroregenerative Therapy

7.7.1.1. Autologous Serum Tears (AST)

7.7.2. Anti-Inflammatory Therapy

7.7.3. Ocular Surface Rehabilitation and Managing Comorbidities

7.7.3.1. Self-Retained Cryopreserved Amniotic Membrane (CAM)

7.7.3.2. Protective Contact Lenses

7.7.4. Systemic Pharmacotherapy

7.7.4.1. First-Line Agents

7.7.4.2. Second Line Agents

7.7.4.3. Third Line Agents

7.7.5. Alternative Therapy

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology

8.3. Assumptions and Rationale: 7MM

8.4. Total Cases of Several Eye Disorders and Surgeries in the 7MM

8.5. Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in the 7MM

8.6. The United States

8.6.1. Number of Cases of Several Eye Disorders and Surgeries in the United States

8.6.2. Number of Cases of NOP in Several Eye Disorders and Surgeries in the United States.

8.7. EU5

8.7.1. Number of Cases of Several Eye Disorders and Surgeries in EU-5

8.7.2. Number of Cases of NOP in Several Eye Disorders and Surgeries in EU-5

8.8. Japan

8.8.1. Number of Cases of Several Eye Disorders and Surgeries in Japan

8.8.2. Number of Cases of NOP in Several Eye Disorders and Surgeries in Japan

9. Patient Journey

10. Emerging Therapies

10.1. Key Cross Competition

10.2. SAF312/libvatrep: Novartis

10.2.1. Drug Description

10.2.2. Clinical Development

10.2.3. Clinical Trials Information

10.2.4. Safety and Efficacy

10.2.5. Product Profile

11. Neuropathic Ocular Pain (NOP): Seven Major Market Analysis

11.1. Key Findings

11.2. Market Methodology

11.3. Market Outlook

11.4. Potential of Current and Emerging Therapies of Neuropathic Ocular Pain (NOP)

11.5. Key Market Forecast Assumptions

11.6. Market size of NOP in the 7MM

11.7. Market size of NOP by Therapies in the 7MM

11.8. Market size of NOP in the United States

11.8.1. Total Market size of NOP in the United States

11.8.2. Market Size by Therapies in the US

11.9. Market size of NOP in EU-5

11.9.1. Total Market size of NOP in EU-5

11.9.2. Market Size of NOP in EU-5 by Therapies

11.10. Market size of NOP in Japan

11.10.1. Total Market size of NOP in Japan

11.10.2. Market Size by Therapies in Japan

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

18. Appendix

18.1. Report Methodology

18.2. Bibliography

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of NOP Market and Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Incidence of Neuropathic Ocular pain in individuals with predisposing conditions

Table 4: Total Cases of Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Table 5: Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Table 6: Number of Cases of Several Eye Disorders and Surgeries in the United States (2018–2030)

Table 7: Number of Cases of NOP in Several Eye Disorders and Surgeries in the United States (2018–2030)

Table 8: Number of Cases of Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Table 9: Number of Cases of NOP in Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Table 10: Number of Cases of Several Eye Disorders and Surgeries in Japan (2018–2030)

Table 11: Number of Cases of NOP in Several Eye Disorders and Surgeries in Japan (2018–2030)

Table 12: Comparison of emerging drugs under development

Table 13: SAF312, Clinical Trial Description, 2021

Table 14: Key Market Forecast Assumptions for SAF312

Table 15: Seven Major Market Size of NOP in USD Million (2018–2030)

Table 16: Market Size of NOP by therapies in the 7MM, in USD Million (2018–2030)

Table 17: United States Market Size of NOP in USD Million (2018–2030)

Table 18: Market Size of NOP by therapies in the 7MM, in USD Million (2018–2030)

Table 19: EU-5 Market Size of NOP in USD Million (2018–2030)

Table 20: Market Size of NOP by therapies in EU-5, in USD Million (2018–2030)

Table 21: Market Size of NOP in Japan, in USD Million (2018–2030)

Table 22: Market Size of NOP by therapies in Japan, in USD Million (2018–2030)

List of Figures

Figure 1: Symptoms of Neuropathic Ocular Pain

Figure 2: Types of Neuropathic Ocular Pain

Figure 3: Causes of Neuropathic Ocular Pain

Figure 4: Clinical Assessment Approach for Patients With Neuropathic Corneal Pain

Figure 5: Diagnosis of Neuropathic Corneal Pain

Figure 6: Corneal Laser in vivo Confocal Microscopy Images of Patients with Neuropathic Corneal Pain

Figure 7: Treatment and management of Neuropathic Ocular Pain

Figure 8: Total Cases of Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Figure 9: Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Figure 10: Number of Cases of Several Eye Disorders and Surgeries in the United States (2018–2030)

Figure 11: Number of Cases of NOP in Several Eye Disorders and Surgeries in the United States (2018–2030)

Figure 12: Number of Cases of Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Figure 13: Number of Cases of NOP in Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Figure 14: Number of Cases of Several Eye Disorders and Surgeries in Japan (2018–2030)

Figure 15: Number of Cases of NOP in Several Eye Disorders and Surgeries in Japan (2018–2030)

Figure 16: Market Size of NOP in the 7MM, USD Millions (2018–2030)

Figure 17: Market Size of NOP by Therapies in the 7MM, USD Millions (2018–2030)

Figure 18: Market Size of NOP in the United States, USD Millions (2018–2030)

Figure 19: Market size of NOP by therapies in the United States, in USD Million (2018–2030)

Figure 20: EU-5 Market Size of NOP, USD Millions (2018–2030)

Figure 21: Market Size of NOP by therapies in EU-5, in USD Million (2018–2030)

Figure 22: Market Size of NOP in Japan, USD Millions (2018–2030)

Figure 23: Market Size of NOP by therapies in Japan, in USD Million (2018–2030)

Figure 24: Market Drivers

Figure 25: Market Barriers

Figure 26: Unmet Needs

Novartis

 

Forward to Friend

Need A Quote